Page 308 - Read Online

Kohla et al. Transforming growth factor β1 in HCC
[9]
the result of Lee et al. , who found that patients with Manuscript review: M.A.S. Kohla, A. Attia, N. Darwesh,
a higher plasma TGF-β1 levels showed significantly H. Taha
lower survival rates than those with a lower plasma
TGF-β1 level ( higher group vs. lower group 47% vs. Financial support and sponsorship
60% at 12 months). This study was funded by the National Liver Institute,
Menoufia University, Egypt.
The association between high TGF-β1 levels and poor
treatment outcomes in advanced HCC patients was Conflicts of interest
anticipated because activation of the TGF-β pathway There are no conflicts of interest.
was linked to angiogenesis and the progression,
invasion, and metastasis of cancer cells in late stage Patient consent
malignancies [19] . A written informed consent was obtained from all
participants in the study.
In this study, ROC curve analysis of TGF-β1 in HCC
showed that the best cut-off value of TGF-β1 for Ethics approval
detection of HCC patients was 301.9 pg/mL with area The study protocol was approved by institute Ethics
under the curve of 0.765 and 95%CI 0.694-0.885, Committee.
the sensitivity and specificity were 72% and 65%
respectively. These results were found to be slightly REFERENCES
different from the published reports by Shehata et al. [13] ,
who reported that with a cut off value of TGF-β1 1. IRAC, Intermediate Agency for Research on Cancer. Epidemiology
(370 pg/mL); the sensitivity and specificity for of HCC. Available from: https://www.iarc.fr [Last accessed on 1 Jan
differentiation of HCC patients were 86.7% and 100% 2016]
respectively, whereas area under the curve was found 2. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in
to be 0.97. This difference is mostly due to differences HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer
in the study population. 2013;13:123-35.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The
contributions of hepatitis B virus and hepatitis C virus infections to
In a systematic review of literature, when AFP of ≥ cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-
20 mcg/L is used as a cut off, the sensitivity of 38.
detecting early HCC is reported to be 25%-65% and 4. Guo X, Wang X. Signaling cross-talk between TGF-beta/BMP and
specificity to be 80%-94% [20] . But here in this study other pathways. Cell Res 2009;19:71-88.
at cut-off point of 20 mcg/L the sensitivity was 72%, 5. Bellam N, Pasche B. TGF-β signaling alterations and colon cancer.
while specificity was 43%. Cancer Treat Res 2010;155:85-103.
6. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato
T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S,
Aiming to increase the sensitivity for early detection Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human
of HCC, combination of TGF-β1 and AFP will raise mesenchymal stem cells xenografted directly to rat liver are differentiated
sensitivity to 90% but decreasing specificity to 32%. into human hepatocytes without fusion. Blood 2005;106:756-63.
So TGF-β1 could be complementary to AFP in the 7. Teicher BA. Malignant cells, directors of malignant process: role of
diagnosis of HCC, particularly for the cases at an transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133-
early stage. 43.
8. Muñoz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, Muro-
Cacho CA, Bàez A. Aberrant methylation inactivates transforming
growth factor beta receptor 1 in head and neck squamous cell
DECLARATIONS carcinoma. Int J Otolrayngol 2009;2009:848695.
9. Lee D, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, Kim KM,
Authors’ contributions Lim YS, Lee HC, Lee YS. Transforming growth factor beta 1 over
expression is closely related to invasiveness of hepatocellular
Concept and design: M.A.S. Kohla, H. Taha carcinoma. Oncology 2012;82:11-8.
Data acquisition: M.A.S. Kohla, A. Attia, N. Darwesh 10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an
Laboratory work: M. Obada update. Hepatology 2011;53:1020-2.
Data analysis: M.A.S. Kohla, A. Attia, N. Darwesh, M. 11. Oh S, Kim E, Kang D, Kim M, Kim JH, Song JJ. Transforming growth
Obada, H. Taha, M.F. Youssef factor-beta gene silencing using adenovirus expressing TGF-β1 or
TGF-β2 shRNA. Cancer Gene Ther 2013;20:94-100.
Statistical analysis: M.F. Youssef 12. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer
Literature search and manuscript preparation: M.A.S. development. Mol Cancer Res 2006;4:221-33.
Kohla, A. Attia, N. Darwesh 13. Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal
Manuscript editing: M.A.S. Kohla, A. Attia, N. growth factor, its receptor and transforming growth factor beta 1 in
Darwesh, H. Taha the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol
300 Hepatoma Research ¦ Volume 3 ¦ December 12, 2017